# PAR PHARMACEUTCL HLDGS -REDH ## No parent of record among the documented ownership edges; 1 supply-chain edge and no export-control designation reaching it on the record Everything below is drawn from what the record carries for this organisation: its documented parents, the constraints that reach it, and the relationships and sites recorded against it. Each claim carries its source on the same line, and a blank means the record holds nothing. Cite PrintScreenshot 0 documented hops above it 1 supply-chain edges · 1 upstream, 0 downstream 0 tracked facilities operated 0 export-control designations reaching it 0 sovereign LP commitments reaching it Scrutica id org-par-pharmaceutcl-hldgs-redh Legal name · 1PAR PHARMACEUTCL HLDGS -REDH ### Chain of title Each hop carries its data source, source URL (where one exists), as-of date, and confidence label on the same line as the parent name. When two sources name different parents for the same hop, both render as alternates; the walker picks no winner. 1. 1. PAR PHARMACEUTCL HLDGS -REDH Starting entity. The walker climbs from here through documented parent / subsidiary edges. Chain terminus [Chain-of-title](/methodology#chain-of-title-walk) terminates at **PAR PHARMACEUTCL HLDGS -REDH**. No further parent is documented. For a public filer that means ultimate beneficial ownership is the dispersed float; for a state-linked entity, that the chain has reached the sovereign apex. ### Suppliers and customers Dollar flows are annual figures from the fiscal year labelled on the row, drawn from SEC segment and >10%-customer disclosures, re-derived company disclosures, or a licensed supply-chain database; per-row source and authority tier on hover. A row without a year means the source does not state the period. Disclosures older than 5 years are tagged _historical_ and ordered below current rows: they record what was disclosed then, and the counterparty may since have been acquired or dissolved. The 3-month Pearson r comes from a licensed supply-chain database; correlation is a coupling proxy for shared market sensitivity, and it is not a causal channel. Sole-source edges are flagged inline. Upstream Suppliers · 1 - [INTELLIPHARMACEUTICS INTL](/companies/org-intellipharmaceutics-intl)historical $1.5M/yr — view full provenanceFY2013 Downstream Customers · 0 [Explore full supply chain graph →](/supply-chain?org=org-par-pharmaceutcl-hldgs-redh) ### Follow PAR PHARMACEUTCL HLDGS -REDH into the analysis The records above join to the platform's analytical surfaces. Each link carries PAR PHARMACEUTCL HLDGS -REDH's own numbers into the tool that acts on them. - [Walk PAR PHARMACEUTCL HLDGS -REDH's 1 supply-chain edge in the graph→ 1 upstream · 0 downstream. The interactive graph opens with PAR PHARMACEUTCL HLDGS -REDH selected, and the cascade simulator propagates seed disruptions across this same edge set, weighted by the curator's substitutability assessment. ](/supply-chain?org=org-par-pharmaceutcl-hldgs-redh) Source coverage One licensed feed is absent here: the corporate-financials extract behind this profile (geographic revenue, segment mix, capital allocation), which is built from listed-company disclosures; PAR PHARMACEUTCL HLDGS -REDH carries no listing or filer identifier, so there is no row for it to load. The public industry classification (SIC, NAICS) is absent as well, and neither absence speaks to what Scrutica holds on PAR PHARMACEUTCL HLDGS -REDH elsewhere. Coverage rules in the [methodology](/methodology#licensed-substrate).